Proactive study: Secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients;L'étude PROactive: Prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2

Revue Medicale de Liege

Volumn 60, Issue 11, 2005, Pages 896-901

  Scheen, A J ^a,b,d   Lefebvre P J ^a,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabetologie Nutrition et Maladies Metaboliques   (Belgium)

^c Fédération Internationale du Diabète ^*

^d CHU SART TILMAN   (Belgium)

Author keywords

Cardiovascular disease; Insulin resistance; Pioglitazone; PPAR ; Prevention; Thiazolidinediones; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; EDEMA; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PLACEBOS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 29344471451     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Beckman JA, Creager MA, Libby P.- Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
2. Paquot N, Scheen AJ.- Prévention cardio-vasculaire chez le patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-274.
3. Yki-Järvinen H.- Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs, 2000, 60, 975-983.
4. Gaede P, Vedel P, Larsen N, et al.- Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
5. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique: plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
6. Krentz AJ, Bailey CJ.- Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
7. Diamant M, Heine RJ.- Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, 63, 1373-1405.
8. Yki-Järvinen H.- Thiazolidinediones. N Engl J Med, 2004, 351, 1106-1118.
9. Scheen AJ, Paquot N.- Récepteurs PPAR-γ, nouvelle cible thérapeutique dans les pathologies métaboliques et cardio-vasculaires. Rev Med Liège, 2005, 60, 89-95.
10. Staels B, Fruchart JC.- Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 2005, 54, 2460-2470.
11. Chiquette E, Ramirez G, DeFronzo R.- A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 2004, 164, 2097-2104.
12. Dormandy J, Charbonnel B, Eckland DJA, Lefèbvre P, Scheen A, et al on behalf of the PROactive investigators. -Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
13. Yki-Järvinen H.- The PROactive study: some answers, many questions. Lancet, 2005, 366, 1241-1242.
14. Scheen AJ.- Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
15. UK Prospective Diabetes Study (UKPDS) Group.-Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-865.
16. Collins R, Armitage J, Parish S, et al.- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2002, 361, 2005-2016.
17. Wald NJ, Law MR.- A strategy to reduce cardiovascular disease by more than 80 %. BMJ, 2003, 326, 1419-1423.
18. Scheen AJ, Lefèbvre PJ, Kulbertus H.- Comment je préviens ... Les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une «polypill» ? Rev Med Liège, 2003, 57, 527-533.
19. Scheen AJ.- Combined thiazolidinedione-insulin therapy. Should we be concerned about safety ? Drug Safety, 2004, 27, 841-856.
20. Clarke PM, Gray AM, Briggs A, et al.- A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004, 47, 1747-1759.
21. Goldberg RB, Kendall DM, Deeg MA et al.- A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005, 28, 1547-54.
22. Home PD, Pocock SJ, Beck-Nielsen H, et al.- Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia, 2005, 48, 1726-1735